Infinatamab Deruxtecan
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Infinatamab Deruxtecan, covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) [Phase 1, Phase 2]